What clinical studies support creatine supplementation for cognitive performance in adults?
Executive summary
Randomized clinical trials and multiple systematic reviews since the 1990s provide a modest, domain-specific signal that creatine monohydrate can improve certain facets of cognition—short-term memory, information-processing speed and performance under metabolic stress—particularly in older or stressed adults, but results are heterogeneous and not uniformly positive across populations or cognitive domains [1] [2] [3]. Major methodological limitations, mixed findings in rigorous large trials, and recent corrigenda temper enthusiasm and mean the evidence supports cautious optimism rather than a clinical recommendation for broad cognitive enhancement [4] [5] [6].
1. What the clinical literature actually tested and found: systematic reviews and meta-analyses
Two comprehensive systematic reviews and a 2024 meta-analysis pooled randomized controlled trials and conclude creatine monohydrate may confer beneficial effects on cognitive function—especially memory, attention time, and processing speed—while stressing the need for larger, more robust trials to confirm effects (Frontiers/PRISMA meta-analysis; PubMed summary) [1] [7]. Earlier systematic reviews focused on healthy individuals similarly reported improvements in short‑term memory and intelligence/reasoning in some trials, with equivocal results for long‑term memory, spatial memory, and executive function [2] [3].
2. Which populations and cognitive tasks show the strongest signals
Evidence is strongest in contexts where brain energy demand is elevated or baseline creatine is low: older adults and people under metabolic stress (sleep deprivation, hypoxia) have repeatedly shown benefit in small studies, and vegetarians (with lower dietary creatine) sometimes respond better than meat‑eaters in memory tasks [2] [8] [5] [3]. Preliminary clinical work in Alzheimer’s disease and small pilot trials report increased brain creatine and improvements on composite cognitive tests after high‑dose supplementation, but those studies are small, sometimes uncontrolled, and framed as feasibility/early‑efficacy work (KU Med / pilot; PubMed pilot) [9] [10] [11].
3. Where the evidence is weak or negative: null trials and regulatory appraisals
Not all high‑quality studies find benefit: regulatory review (EFSA) highlights a randomized trial that found no cognitive improvement in young adults, and a recent corrigendum to a meta‑analysis reports no significant pooled effect on attention (overall SMD 0.22; CI crossing zero), illustrating heterogeneity and non‑significance in some domains [12] [4]. Commentators also note that the largest and most rigorous long‑term trials in neurodegenerative disease settings—such as a multicenter Parkinson’s trial—found no clinical benefit, underscoring that promising mechanistic rationale has not always translated to clinical effect in large samples [6] [5].
4. Mechanistic plausibility and intermediate biomarkers
Biological plausibility is solid: oral creatine increases brain creatine content up to a saturation threshold, and creatine plays a central role in cellular energy buffering—mechanisms used to justify cognitive benefit, particularly under energy stress (sleep loss, hypoxia) [5] [8]. Imaging and spectroscopy studies in pilots show increased brain total creatine after supplementation, which supports a mechanistic bridge between supplement intake and brain bioenergetics, though demonstrating that this reliably yields cognitive improvement requires larger trials [10] [11].
5. Methodological limits, heterogeneity and what’s needed next
Across trials there is wide variation in dose (from single doses to multi‑gram loading regimens), duration (single dose to months), designs (crossover, parallel, single‑arm), populations (young, elderly, vegetarians, clinical populations), and cognitive tests—creating heterogeneity that diminishes pooled confidence and produces mixed meta‑analytic results [1] [2] [5]. Authors of recent reviews explicitly call for larger, well‑powered RCTs with standardized cognitive batteries, objective measures of brain creatine, and targeted populations (older adults, cognitively impaired, or metabolically stressed) to settle where benefits are real and clinically meaningful [7] [1] [13].
6. Bottom line
Clinical studies provide plausible, reproducible signals that creatine monohydrate can improve certain cognitive outcomes in some adults—notably short‑term memory and performance under metabolic stress—and small pilot trials in Alzheimer’s disease show feasibility and early positive signals, but heterogeneity, null high‑quality trials, and regulatory caution mean the evidence is not definitive and cannot yet support broad claims that creatine is a general cognitive enhancer for all adults [1] [2] [10] [12] [6]. Future large, rigorous trials that measure brain creatine and focus on at‑risk or stressed populations are required to move from promise to proof [7] [5].